The Challenges of Switching Therapies in an Evolving Multiple Biosimilars Landscape: A Narrative Review of Current Evidence

With the increasing availability of biosimilars, the practice of switching therapies for non-medical reasons between an originator biologic and an analogous biosimilar has become more common. The evidence to support this practice mostly comes from single-switch randomized controlled trials (RCTs) an...

Descripción completa

Detalles Bibliográficos
Autores principales: Feagan, Brian G., Marabani, Mona, Wu, Jashin J., Faccin, Freddy, Spronk, Claire, Castañeda-Hernández, Gilberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7547992/
https://www.ncbi.nlm.nih.gov/pubmed/32910420
http://dx.doi.org/10.1007/s12325-020-01472-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7547992/
https://www.ncbi.nlm.nih.gov/pubmed/32910420
http://dx.doi.org/10.1007/s12325-020-01472-1

Ejemplares similares